

The Importance of Liver-Fatty Acid Binding Protein in Diagnosis of Liver Damage in Patients with Acute Hepatitis

OZLEM OZER CAKIR¹, AYSUN TOKER², HUSEYIN ATASEVEN³, ALI DEMIR⁴, HAKKI POLAT⁵

ABSTRACT

Introduction: Acute hepatitis is acute inflammation of liver elicited by a large number of causes. It sometimes spontaneously recovers, sometimes may progress to chronic hepatitis. Liver-Fatty Acid Binding Protein (L-FABP) is a small protein that is abundant in hepatocytes, and which binds most of the long-chain fatty acids present in the cytosol.

Aim: The present study aimed to investigate the levels of serum and urine L-FABP in acute hepatitis and diagnostic value of serum and urine L-FABP levels in patients with acute hepatitis.

Materials and Methods: The present study included a total of 85 patients. Total number of patients with acute hepatitis were 17 (five of acute hepatitis B, one of acute hepatitis A, two of acute hepatitis C, five of autoimmune hepatitis and four of toxic hepatitis), 19 of hepatic encephalopathy, 29 of liver cirrhosis, and 20 controls were included. Serum and urinary L-FABP levels were analyzed by the Enzyme-Linked Immunosorbent Assay (ELISA).

Results: Serum L-FABP levels were 9110 ± 3352.5 , 9410 ± 1355 , 9715 ± 2462 and 3672 ± 982.5 ng/l in patients with acute hepatitis, hepatic encephalopathy and cirrhosis and control subjects, respectively. There were statistically significant positive correlations between serum levels of L-FABP and Aspartate Aminotransferases (AST), Alanine Aminotransferases (ALT), Creatinine (Cre) and Gamma Glutamyl Transferases (GGT) ($p < 0.001$, $p < 0.001$, $p < 0.001$ and $p < 0.001$, respectively). While the cut-off value of serum L-FABP for all of the patients was 5183 ng/l ($p < 0.001$ and Area Under Curve (AUC) 0.985}, the sensitivity and specificity were 95.4% and 100%, respectively. Positive and negative predictive values for serum L-FABP were 100% and 87%, respectively.

Conclusion: Serum and urine L-FABP may be a new diagnostic marker for liver damage in patients with acute hepatitis. However, our study showed that except of aminotransferases, L-FABP should be used for diagnosis of liver damage in patients with acute hepatitis, chronic hepatitis and also cirrhosis.

Keywords: Cirrhosis, Hepatic encephalopathy, Steatohepatitis

INTRODUCTION

Acute hepatitis can be due to a number of causes. Acute inflammation of the liver usually recovers in a few months [1,2]. Acute hepatitis sometimes progress to chronic hepatitis, and it rarely leads to acute liver failure. The most frequent cause of acute hepatitis is infection (especially, acute viral hepatitis). It may also occur as a result of use of some drugs and/or herbals, overdose of drugs, exposure to toxic chemicals (alcohol) [3,4]. Other causes of acute hepatitis are autoimmune hepatitis and mushroom poisoning. Symptoms vary from mild to severe with fatigue, pain, itching, fever, and jaundice. Liver function tests (LFT) are used for diagnosis. ALT should be 10-50 times higher than normal limits (for ALT $> 2,000$ IU, drug history should be considered, acetaminophen level if appropriate). Elevated AST, GGT and total bilirubin levels could be observed in patients with acute hepatitis. Healing process usually occurs in patients with acute hepatitis within a few months. Acute hepatitis may sometimes deteriorate and a liver transplant may be needed for improvement [5,6].

FABPs are a family of 15-kDa proteins. There are nine different FABPs that have been identified and named according to the tissues [7]. L-FABP is expressed mainly in the liver, but small quantities are also found in the kidney and small intestine [7,8]. Till date, a large number of studies on different types of FABPs have shown that these proteins are associated with tissue damage, including myocardial injury, and damage to other organs such as lungs, kidneys, intestine and liver [9-17].

L-FABP is a small molecule that is expressed in the liver. Till date, some studies including chronic hepatitis C, non-alcoholic

steatohepatitis and non-alcoholic fatty liver disease have shown that, serum L-FABP could be a new diagnostic marker to detect liver injury [18-20].

Hence, we aimed to investigate the relationship between serum/urine L-FABP levels and liver damage in patients with acute hepatitis and determination of diagnostic value in prediction of liver damage.

MATERIALS AND METHODS

This was a prospective study. This study was administrated at the gastroenterology clinic of an Necmettin Erbakan University, Meram school of Medicine Hospital. The study protocol was approved by the local Ethical Committee. All patients or first degree relatives and control subjects signed informed consent forms. Consecutive patients with acute hepatitis, hepatic encephalopathy and stable cirrhosis who were admitted to gastroenterology polyclinic or clinic were enrolled for evaluation of suitability for the study between March, 2012 and March, 2013. The exclusion criteria were as follows: malignancy, hepatocellular carcinoma, active cerebrovascular event, shock, trauma, active infection, inflammatory diseases, renal diseases, use of nephrotoxic drug, intoxication, metabolic disorders, brain disorders, psychiatric diseases, use of sedatives or psychiatric drugs.

Participants

Four groups of patients were included in our study. Group 1 consisted of patients with acute hepatitis. These patients had no previous liver disease. Their transaminases were 10-50 times higher than the

normal limits. We enrolled patients who had ALT above 300 IU. Group 2 consisted of patients with overt hepatic encephalopathy. These patients also had a clinical and/or histopathologic diagnosis of cirrhosis. These patients had overt hepatic encephalopathy throughout their hospitalization. We evaluated grades of hepatic encephalopathy based on West Haven criteria for semiquantitative grading of mental state. These grades are as follows: Grade 1- trivial lack of awareness, euphoria or anxiety, shortened attention span, impaired performance of addition; Grade 2- lethargy or apathy, minimal disorientation for time or place, subtle personality change, inappropriate behaviour, impaired performance of subtraction; Grade 3-somnolence to semi-stupor (but responsive to verbal stimuli), confusion, gross disorientation; Grade 4-coma (unresponsive to verbal or noxious stimuli) [21]. Group 3 consisted of patients with stable cirrhosis. These patients had diagnosis of cirrhosis but had no serious complication of cirrhosis such as hepatorenal syndrome, bleeding of varix, hepatic encephalopathy, or hepatopulmonary syndrome. Group 4 consisted of control subjects. These were the subjects who came for check-up at the gastroenterology polyclinic. They did not have any disease.

An ultrasonographic evaluation was performed for severity of ascites as mild, moderate or severe. Grades of ascites were as follows: mild ascites (Grade 1) – only detectable by ultrasound examination; moderate ascites (Grade 2) – that is manifested as moderate symmetrical distension of the abdomen; severe ascites (Grade 3) – with marked abdominal distension [22].

Clinicodemographic Data and Collection of Blood Samples

Blood and urine samples were obtained from patients and control subjects in the all groups for analysis. Each patient who was suitable for inclusion in the study underwent a physical examination, and detailed medical history was recorded. Serum and urine L-FABP levels were analysed from collected samples.

Serum and urine samples were centrifuged at 4°C and 1,000 g for 15 minutes. These samples were stored at -80°C until analysis. Blood and urine samples were analysed by biochemists using Human L-FABP ELISA kit (L-FABP, E91566Hu, USCN Life Science Houston, TX, USA). Briefly, microtitre plates were coated with a monoclonal antibody against human L-FABP and 100 µL serum and urine samples were added and incubated for one hr at 37°C. After washing, each one was incubated with 100 µl biotinylated monoclonal antibody for one hour at 37°C. The solution was aspirated and washed three times, followed by addition of 100 µl avidin-conjugated HRP and incubation for one hour at 37°C. After washing five times, 100 µl tetramethylbenzidine substrate was added for colour development in the dark room, which was read after 10-30 min at 450 nm using an ELISA reader (Benchmark Plus, BioRad, Hercules, CA, USA).

STATISTICAL ANALYSIS

Data analysis was performed using the Statistical Package for the Social Sciences (SPSS) for Windows, version 11.5 (SPSS Inc., Chicago, IL, United States). Whether the continuous variables were distributed normally or not was determined by Kolmogorov Smirnov test. Levene test was used for the evaluation of homogeneity of variances. Data were expressed as median (IQR).

Whether the differences in medians among groups were statistically significant or not was evaluated by Kruskal Wallis test. When the p-value from Kruskal Wallis test was statistically significant, Conover's multiple comparison test was used to find which group differed from the others. Categorical data were analyzed by Pearson's chi-square test. Degrees of association between continuous variables were evaluated by Spearman's rank correlation analyses.

The optimal cut-off points of serum and urinary L-FABP to discriminate controls from other case groups were evaluated

by ROC analyses as giving the maximum sum of sensitivity and specificity for the significant test. Diagnostic performance (i.e. sensitivity, specificity, positive and negative predictive values) for each clinical measurement were also calculated.

A p-value less than 0.05 was considered statistically significant. For all possible multiple comparisons the Bonferroni Correction was applied for controlling type I error.

RESULTS

A total of 85 patients with 17 of acute hepatitis (five of acute hepatitis B, one of acute hepatitis A, two of acute hepatitis C, five of autoimmune hepatitis and four of toxic hepatitis), 19 of hepatic encephalopathy, 29 of liver cirrhosis, and 20 control subjects were included in the study.

There was no statistically significant difference between the groups in terms of gender ($p=0.307$). There was no statistically significant difference between acute hepatitis and control groups in terms of age ($p>0.05$). Demographic and clinical features are shown at [Table/Fig-1].

Serum L-FABP levels were 9110 ± 3352.5 , 9410 ± 1355 , 9715 ± 2462 and 3672 ± 982.5 ng/l in patients with acute hepatitis, hepatic encephalopathy, cirrhosis and control subjects, respectively.

Urine L-FABP levels were 8730 ± 1155 , 9896 ± 1108 , 9350 ± 854.5 and 3391.5 ± 312.5 ng/l in patients with acute hepatitis, hepatic encephalopathy, cirrhosis and control subjects, respectively.

ALT levels in patients with acute hepatitis was significantly higher than hepatic encephalopathy and stable cirrhosis, and control subjects, respectively ($p<0.001$, $p<0.001$ and $p<0.001$).

AST levels in patients with acute hepatitis was significantly higher than hepatic encephalopathy and stable cirrhosis, and control subjects, respectively ($p=0.002$, $p<0.001$ and $p<0.001$).

Serum Cre levels in patients with hepatic encephalopathy was significantly higher than acute hepatitis and stable cirrhosis, and control subjects, respectively ($p<0.001$, $p<0.001$ and $p<0.001$). Therefore, Cre levels in patients with stable cirrhosis was significantly higher than control subjects ($p=0.015$). There was no statistically significant difference between acute hepatitis and control groups in terms of Cre levels ($p>0.05$).

GGT levels in patients with acute hepatitis was significantly higher than hepatic encephalopathy and stable cirrhosis, and control subjects, respectively ($p<0.01$, $p<0.01$ and $p<0.001$).

Serum L-FABP levels in patients with acute hepatitis, hepatic encephalopathy and stable cirrhosis were significantly higher than control subjects, respectively ($p<0.001$, $p<0.001$ and $p<0.001$) [Table/Fig-2].

Urine L-FABP levels in patients with acute hepatitis, hepatic encephalopathy and stable cirrhosis were significantly higher than control subjects, respectively ($p<0.001$, $p<0.001$ and $p<0.001$). At the same time, urine L-FABP levels in patients with hepatic encephalopathy and stable cirrhosis were significantly higher than patients with acute hepatitis, respectively ($p<0.001$ and $p=0.006$) [Table/Fig-2].

There were statistically significant strong positive correlation between serum L-FABP levels and AST, ALT, Cre and GGT ($p<0.001$). There were statistically significant positive correlation between urine L-FABP levels and AST, ALT, Cre and GGT ($p<0.05$). Correlation of several laboratory parameters with serum and urine L-FABP levels are shown in [Table/Fig-3].

ROC curve analysis showed that the plot of the serum L-FABP and urine L-FABP, could be the diagnostic marker of liver damage (AUC=0.985 and AUC=1.000, respectively) [Table/Fig-4].

While cut-off value of serum L-FABP was 5183 ng/l for all of the patients, the sensitivity and specificity were 95.4% and 100%, respectively. Positive and negative predictive values for serum

Variables	Acute Hepatitis (n=17)	Hepatic Encephalopathy (n=19)	Stable Cirrhosis (n=29)	Control (n=20)	p-value
Age	48.8±18.2 ^{a,b}	65.3±13.9 ^{a,c}	63±12.8 ^{b,d}	42.7±16.9 ^{c,d}	<0.001†
Gender					0.307‡
Female	8 (47.1%)	7 (36.8%)	10 (34.5%)	12 (60%)	
Male	9 (52.9%)	12 (63.2%)	19 (65.5%)	8 (40%)	
AST	453±395.5 ^{a,b,e}	67 ±60 ^{a,c}	47±28.5 ^{b,d}	15±5.5 ^{c,d,e}	<0.001†
ALT	616±437 ^{a,b,e}	44±36 ^{a,c}	29±19 ^{b,d}	14.5±9 ^{c,d,e}	<0.001†
CRE	0.69±0.26 ^a	1.21±1.19 ^{a,c,f}	0.80±0.38 ^{d,f}	0.60±0.24 ^c	<0.001†
GGT	140±131 ^{a,b,e}	50±66 ^{a,c}	38±32.5 ^{b,d}	21±6.25 ^{c,d,e}	<0.001†
Serum L-FABP	9110±3352.5 ^e	9410±1355 ^c	9715±2462.5 ^d	3672±982.5 ^{c,d,e}	<0.001†
Urine L-FABP	8730±1155 ^{a,b,e}	9896±1108 ^{a,c}	9350±854 ^{b,d}	3391.5±312.5 ^{c,d,e}	<0.001†

[Table/Fig-1]: Demographic and clinical features.

† Kruskal Wallis test, ‡ Pearson's Chi-square test

a: There was statistically significant difference between acute hepatitis and hepatic encephalopathy (p<0.01)


b: There was statistically significant difference between acute hepatitis and stable cirrhosis (p<0.01)

c: There was statistically significant difference between hepatic encephalopathy and control subjects (p<0.05)

d: There was statistically significant difference between stable cirrhosis and control subjects (p<0.001)

e: There was statistically significant difference between acute hepatitis and control subjects (p<0.001)

f: There was statistically significant difference between HE and SC (p<0.001).



[Table/Fig-2]: Serum and urine L-FABP levels in groups.

Serum and urine L-FABP levels in patients with acute hepatitis, hepatic encephalopathy and stable cirrhosis were significantly higher than control subjects (*p<0.05). Urine L-FABP levels in patients with hepatic encephalopathy and stable cirrhosis were significantly higher than patients with acute hepatitis, respectively (* p<0.001 and Δ p=0.006).

*AH: Acute Hepatitis, HE: Hepatic Encephalopathy, SC: Stable Cirrhosis, L-FABP: Liver Fatty Acid Binding Protein

	Serum L-FABP		Urine L-FABP	
	R	p†	r	p †
AST	0.467	<0.001	0.400	<0.001
ALT	0.348	<0.001	0.326	0.002
CRE	0.378	<0.001	0.256	0.018
GGT	0.471	<0.001	0.321	0.003

[Table/Fig-3]: Correlation analysis between L-FABP and laboratory parameters.


† Spearman's Rank Correlation

AST: Aspartate transaminase, ALT: Alanine aminotransferase, CRE: Creatinine, GGT: Gamma glutamyl transferase

L-FABP were 100% and 87%, respectively. While cut-off value of urine L-FABP was 4367 ng/l for all of the patients, the sensitivity and specificity were 100% and 100%, respectively. Positive and negative predictive values for urine L-FABP were 100% and 100%, respectively. A comparison between groups and control are shown in [Table/Fig-5,6].

DISCUSSION

This is the first prospective study that investigates the cut-off level of serum and urine L-FABP for diagnosing liver damage in patients with acute hepatitis, hepatic encephalopathy and stable cirrhosis. Our data suggest that serum and urine L-FABP is able to diagnose liver damage. This study showed good correlation between serum and/or urine L-FABP levels and AST, ALT, Cre, and GGT.



[Table/Fig-4]: ROC curve plots of the serum L-FABP and urine L-FABP in diagnostic marker of liver damage.

A previous study showed that L-FABP is a diagnostic marker for the detection of early hepatocellular injury in liver transplant patients and indicated that L-FABP is a small molecule that was elevated early in association with acute liver injury. Therefore, L-FABP appears to be superior to other liver enzymes including ALT, AST and glutathione S-transferase (GST) [23]. Our study showed that L-FABP has some advantages over other liver enzymes, because L-FABP is elevated in all types of liver damage, whereas the others are not.

A study showed a correlation between Knodell score and L-FABP, but there was no correlation between Knodell score with ALT or AST. Therefore, it was indicated that L-FABP could be superior to ALT and AST [18]. Another study suggested that elevation of serum L-FABP levels were associated with the degree of fibrosis and inflammation, indicating that serum L-FABP could be a non-invasive marker in determining the severity of fibrosis and inflammation in patients with non-alcoholic steatohepatitis [19]. One study demonstrated that elevated serum L-FABP levels were related to ongoing liver damage in patients with non-alcoholic fatty liver disease [20]. Our study provided a comparison between patients with acute hepatitis, cirrhosis and controls based on serum and urine L-FABP levels as a

	Cut- off	AUC (95%CI)	Sens. %	Spec. %	PPV%	NPV%	p-value
All Patients (serum L-FABP)	>5183	0.985 (0.965-1.000*)	95.4%	100%	100%	87%	<0.001
AH (serum L-FABP)	>4818	0.944 (0.868-1.000*)	88.2%	95%	93.8%	90.5%	<0.001
HE (serum L-FABP)	>5875.5	1.000 (1.000-1.000)	100%	100%	100%	100%	<0.001
SC (serum L-FABP)	>5415.5	1.000 (1.000-1.000)	100%	100%	100%	100%	<0.001

[Table/Fig-5]: A comparison between each group and control in prediction of diagnostic marker of serum L-FABP levels.

*95% CI upper limit>1.000

AUC, area under the curve; CI, confidence interval; Sens, sensitivity; Spec, specificity; PPV, positive predictive value; NPV, Negative predictive value
AH: Acute Hepatitis, HE: Hepatic Encephalopathy, SC: Stable Cirrhosis

	Cut- off	AUC (95%CI)	Sens. %	Spec. %	PPV%	NPV%	p value
All patients (urine L-FABP)	>4367	1.000 (1.000-1.000)	100%	100%	100%	100%	<0.001
AH (urine L-FABP)	>5294.5	1.000 (1.000-1.000)	100%	100%	100%	100%	<0.001
HE (urine L-FABP)	>5359.5	1.000 (1.000-1.000)	100%	100%	100%	100%	<0.001
SC (urine L-FABP)	>4367	1.000 (1.000-1.000)	100%	100%	100%	100%	<0.001

[Table/Fig-6]: A comparison between each group and control in prediction of diagnostic marker of urine L-FABP levels.

AH: Acute Hepatitis, HE: Hepatic Encephalopathy, SC: Stable Cirrhosis

AUC: area under the curve; CI: confidence interval; Sens: sensitivity; Spec: specificity; PPV: positive predictive value; NPV: Negative predictive value

diagnostic marker. According to our data, serum and urine L-FABP are useful in detecting liver damage.

In a previous study, L-FABP levels increased significantly during liver mobilization that is associated with hepatocellular damage and liver inflammation [17]. Some studies showed elevated L-FABP levels in patients with Pringle manoeuvre during liver surgery; whereas, aminotransferases did not change significantly [24,25]. One study showed that plasma levels of L-FABP correlated well with warm ischaemia and concomitant hepatocellular damage in liver transplantation from non-heart-beating donors. Therefore, they said that monitoring of post-transplant L-FABP plasma levels was a valuable new tool to quantify early the extent of parenchymal cell damage of non-heart-beating donor liver and to predict their viability and function [26].

Other mechanisms of liver damage involve the toxic effects of alcohol and drugs. A previous study showed that alcohol consumption caused a significant increase in serum I- and L-FABP levels, compared to water consumption [27]. Another study described the hepatotoxic effects of pyrazinamide and the role of the Peroxisome Proliferator-Activated Receptor Alpha (PPAR α) and its target genes in the downstream pathway including L-FABP, Lpl, Cpt-1b, Acaa1, Apo-A1 and Me1 in this process. At the same time, they found that pyrazinamide induced the liver lipid metabolism disorder and PPAR α expression was down-regulated which had a significant inverse correlation with liver injury degree [16].

LIMITATION

There are some limitations in our study. Firstly, the number of patients is relatively small. Larger studies should be considered to clarify diagnostic value of serum and urine L-FABP in liver damage. Secondly, there are significantly difference between hepatic encephalopathy, stable cirrhosis and control groups in terms of age but not in acute hepatitis and control groups.

CONCLUSION

Our study showed that serum and urine L-FABP levels were strongly correlated with liver damage. Therefore, these biomarkers could be a non-invasive diagnostic marker for liver damage. Our study suggested that when the liver is damaged L-FABP is always elevated, but other liver enzymes may found to be normal. Therefore, estimation of L-FABP should be a priority compared to other liver enzymes, and could be used for follow-up of the progress of liver damage.

Financial Support: This study was supported by Necmettin Erbakan University Scientific Research Projects Fund.

REFERENCES

- Dienstag JL. Chapter 360: Acute Viral Hepatitis. In Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J (Eds.). Harrison's Principles of Internal Medicine, 19th ed., New York, NY: McGraw-Hill; 2015.
- Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525-34.
- Dienstag JL. Chapter 306. Chronic Hepatitis. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J (Eds.). Harrison's Principles of Internal Medicine, 18th Edn., New York, NY: McGraw-Hill; 2012.
- Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013;10(11): 627-36.
- Basra S, Anand BS. Definition, epidemiology and magnitude of alcoholic hepatitis. World J of Hepatol. 2011;3(5):108-13.
- Friedman LS. Chapter 16: Liver, Biliary Tract, & Pancreas Disorders. In Papadakis M, McPhee SJ, Rabow MW. Current Medical Diagnosis & Treatment 2016, 55th Edn. McGraw Hill; 2015.
- Glatz JF, van der Vusse GJ. Cellular fatty acid-binding proteins: Their function and physiological signification. Prog Lipid Res. 1996;3:243-82.
- Bass NM, Barker ME, Manning JA, Jones AL, Ockner RK. Acinar heterogeneity of fatty acid-binding protein in the livers of male, female and clofibrate treated rats. Hepatology. 1989;9:12-21.
- Bajaj A, Rathor P, Sehgal V, Kabak B, Shetty A, Al Masalmeh O, et al. Prognostic value of biomarkers in acute non-massive pulmonary embolism: a systematic review and meta-analysis. Lung. 2015;193(5):639-51.
- Khadaroo RG, Fortis S, Salim SY, Streutker C, Churchill TA, Zhang H. I-FABP as biomarker for the early diagnosis of acute mesenteric ischemia and resultant lung injury. PLoS One. 2014;9(12):e115242.
- Hoo RL, Lee IP, Zhou M, Wong JY, Hui X, Xu A, et al. Pharmacological inhibition of adipocyte fatty acid binding protein alleviates both acute liver injury and non-alcoholic steatohepatitis in mice. J Hepatol. 2013;58(2):358-64.
- Gururajan P, Gurumurthy P, Nayar P, Srinivasa Nageswara Rao G, Babu S, Cherian KM. Heart fatty acid binding protein (H-FABP) as a diagnostic biomarker in patients with acute coronary syndrome. Heart Lung Circ. 2010;19(11):660-64.
- Kabekkodu SP, Mananje SR, Saya RP. A study on the role of heart type fatty acid binding protein in the diagnosis of acute myocardial infarction. J Clin Diagn Res. 2016;10(1):OC07-10.
- Koo TY, Jeong JC, Lee Y, Ko KP, Lee KB, Lee S, et al. Pre-transplant evaluation of donor urinary biomarkers can predict reduced graft function after deceased donor kidney transplantation. Medicine (Baltimore). 2016;95(11):e3076.
- Basu RK, Kaddourah A, Terrell T, Mottes T, Arnold P, Jacobs J, et al. Assessment of worldwide acute kidney injury, renal angina and epidemiology in critically ill children (AWARE): A prospective study to improve diagnostic precision. J Clin Trials. 2015;5(3): 222.
- Zhang Y, Guo H, Hassan HM, Ding PP, Su Y, Song Y, et al. Pyrazinamide induced hepatic injury in rats through inhibiting the PPAR α pathway. J Appl Toxicol. 2016;36(12):1579-90.
- van den Broek MA, Shiri-Sverdlov R, Schreurs JJ, Bloemen JG, Blegghs V, Rensen SS, et al. Liver manipulation during liver surgery in humans is associated with hepatocellular damage and hepatic inflammation. Liver Int. 2013;33(4):633-41.
- Akbal E, Köklü S, Koçak E, Cakal B, Güneş F, Başar O, et al. Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection. Arch Med Res. 2013;44(1):34-38.
- Ozenirler S, Degertekin CK, Erkan G, Elbeg Ş, Tuncer C, Kandilci U, et al. Serum liver fatty acid binding protein shows good correlation with liver histology in NASH. Hepatogastroenterology. 2013;60(125):1095-100.
- Akbal E, Koçak E, Akyürek Ö, Köklü S, Batgi H, Şenes M. Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease. Wien Klin Wochenschr 2016;128:48-52.

- [21] Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. *Hepatology*. 2002; 35:716-21.
- [22] Wong F. Management of ascites in cirrhosis. *J Gastroenterol Hepatol*. 2012;27:11-20.
- [23] Pelsers MM, Morovat A, Alexander GJ, Hermens WT, Trull AK, Glatz JF. Liver fatty acid binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. *Clin Chem*. 2002;48:2055-57.
- [24] van den Broek MAJ, Bloemen JG, Dello SAWG, van de Poll MCG, Olde Damink SWM, Dejong CHC. Randomized controlled trial analyzing the effect of 15 or 30 min intermittent Pringle maneuver on hepatocellular damage during liver surgery. *J Hepatol*. 2011;55:337-45.
- [25] van de Poll MC, Derikx JP, Buurman WA, Peters WH, Roelofs HM, Wigmore SJ, et al. Liver manipulation causes hepatocyte injury and precedes systemic inflammation in patients undergoing liver resection. *World J Surg*. 2007;31:2033-38.
- [26] Monbaliu D, de Vries B, Crabbé T, van Heurn E, Verwaest C, Roskams T, et al. Liver fatty acid-binding protein: An early and sensitive plasma marker of hepatocellular damage and a reliable predictor of graft viability after liver transplantation from non-heart-beating donors. *Transplant Proc*. 2005;37(1):413-16.
- [27] de Jong WJ, Cleveringa AM, Greijdanus B, Meyer P, Heineman E, Hulscher JB. The effect of acute alcohol intoxication on gut wall integrity in healthy male volunteers: A randomized controlled trial. *Alcohol*. 2015;49(1):65-70.

PARTICULARS OF CONTRIBUTORS:

1. Department of Gastroenterology and Hepatology, Konya Education and Research Hospital, Konya, Meram, Turkey.
2. Department of Biochemistry, Necmettin Erbakan University, Meram school of Medicine, Konya, Meram, Turkey.
3. Department of Gastroenterology and Hepatology, Necmettin Erbakan University, Meram school of Medicine, Konya, Meram, Turkey.
4. Department of Gastroenterology and Hepatology, Necmettin Erbakan University, Meram school of Medicine, Konya, Meram, Turkey.
5. Department of Gastroenterology and Hepatology, Necmettin Erbakan University, Meram school of Medicine, Konya, Meram, Turkey.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Ozlem Ozer Cakir,
Department of Gastroenterology and Hepatology, Konya Education and Research Hospital, 42080, Konya,
Meram, Turkey.
E-mail: tansozlem@yahoo.com

Date of Submission: **Oct 21, 2016**
Date of Peer Review: **Dec 16, 2016**
Date of Acceptance: **Jan 06, 2017**
Date of Publishing: **Apr 01, 2017**

FINANCIAL OR OTHER COMPETING INTERESTS: None.